<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743520</url>
  </required_header>
  <id_info>
    <org_study_id>20150860</org_study_id>
    <nct_id>NCT02743520</nct_id>
  </id_info>
  <brief_title>Arrhythmia Detection In Obstructive Sleep Apnea (ADIOS)</brief_title>
  <acronym>ADIOS</acronym>
  <official_title>Early Identification of Patients With Coexisting Atrial Fibrillation and Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn about arrhythmia detection in obstructive&#xD;
      sleep apnea (OSA). For several years patients with OSA have an increased likelihood of having&#xD;
      irregular heartbeats. This study will determine how often patients with OSA have irregular&#xD;
      heartbeats. This study will also define which OSA patients are most likely to have irregular&#xD;
      heartbeats.&#xD;
&#xD;
      The participant is being asked to be in the study because the participant has been diagnosed&#xD;
      with obstructive sleep apnea (OSA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 6, 2017</start_date>
  <completion_date type="Actual">April 3, 2019</completion_date>
  <primary_completion_date type="Actual">April 3, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Definite Atrial Fibrillation (Defined as an Irregularly Irregular Rhythm With Absence of p Waves)</measure>
    <time_frame>Week 2</time_frame>
    <description>New cases of atrial fibrillation as evaluated by the LifestarAct III.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Frequent Ventricular Premature Contractions</measure>
    <time_frame>week 2</time_frame>
    <description>More than 100 contraction during a 24 hour period as evaluated by the LifestarAct III.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longest Duration of Atrial Fibrillation</measure>
    <time_frame>Week 2</time_frame>
    <description>Longest duration of Atrial Fibrillation in minutes compare to the rests of Atrial Fibrillation in a 24 hours, as evaluated by the LifestarAct III.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation Episodes Lasting More Than Six Minutes</measure>
    <time_frame>Week 2</time_frame>
    <description>In participants with atrial fibrillation as evaluated by the LifestarAct III.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Frequent Premature Atrial Contractions</measure>
    <time_frame>Week 2</time_frame>
    <description>More than 100 contraction during a 24 hour period as evaluated by the LifestarAct III.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Arrhythmia</condition>
  <condition>Stroke, Cardiovascular</condition>
  <arm_group>
    <arm_group_label>Cardiac event monitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will under go evaluation with a two week cardiac event monitor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Lifestar Act III</intervention_name>
    <description>The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.</description>
    <arm_group_label>Cardiac event monitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of OSA within the last 12 months&#xD;
&#xD;
          2. No previous diagnosis of atrial fibrillation&#xD;
&#xD;
          3. Able and willing to follow-up as an outpatient&#xD;
&#xD;
          4. Age 40-85 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life expectancy &lt; 2 years&#xD;
&#xD;
          2. Dementia or other neurologic condition which would make outpatient follow-up difficult&#xD;
&#xD;
          3. CHADS score &lt;2&#xD;
&#xD;
          4. Alcohol or drug abuse which would interfere with outpatient follow-up&#xD;
&#xD;
          5. Severe Congestive heart failure (NYHA class 3 or 4) or use of left ventricular assist&#xD;
             device.&#xD;
&#xD;
          6. Current dialysis treatment or planned treatment within 12 months&#xD;
&#xD;
          7. Known bleeding disorder or prothrombin time &gt;15 seconds&#xD;
&#xD;
          8. Mechanical heart valve requiring anticoagulation&#xD;
&#xD;
          9. Moderate to severe mitral stenosis or regurgitation&#xD;
&#xD;
         10. Prior clinical diagnosis of ischemic stroke (radiologic infarcts are not excluded)&#xD;
&#xD;
         11. Chronic obstructive pulmonary disease with oxygen dependence&#xD;
&#xD;
         12. Pregnant patients or patients that plan to become pregnant within the course of the&#xD;
             study*.&#xD;
&#xD;
         13. Patients with anticipated need for a pacemaker during the course of the study *If any&#xD;
             patients become pregnant during the course of the study, pregnancy outcomes will not&#xD;
             be followed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto R Ramos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <results_first_submitted>October 6, 2020</results_first_submitted>
  <results_first_submitted_qc>October 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2020</results_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Alberto Rafael Ramos</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>sleep apnea</keyword>
  <keyword>arrhythmia detection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02743520/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cardiac Event Monitor</title>
          <description>Participants will under go evaluation with a two week cardiac event monitor.&#xD;
The Lifestar Act III: The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cardiac Event Monitor</title>
          <description>Participants will under go evaluation with a two week cardiac event monitor.&#xD;
The Lifestar Act III: The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.3" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Definite Atrial Fibrillation (Defined as an Irregularly Irregular Rhythm With Absence of p Waves)</title>
        <description>New cases of atrial fibrillation as evaluated by the LifestarAct III.</description>
        <time_frame>Week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cardiac Event Monitor</title>
            <description>Participants will under go evaluation with a two week cardiac event monitor.&#xD;
The Lifestar Act III: The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Definite Atrial Fibrillation (Defined as an Irregularly Irregular Rhythm With Absence of p Waves)</title>
          <description>New cases of atrial fibrillation as evaluated by the LifestarAct III.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Frequent Ventricular Premature Contractions</title>
        <description>More than 100 contraction during a 24 hour period as evaluated by the LifestarAct III.</description>
        <time_frame>week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cardiac Event Monitor</title>
            <description>Participants will under go evaluation with a two week cardiac event monitor.&#xD;
The Lifestar Act III: The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Frequent Ventricular Premature Contractions</title>
          <description>More than 100 contraction during a 24 hour period as evaluated by the LifestarAct III.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Longest Duration of Atrial Fibrillation</title>
        <description>Longest duration of Atrial Fibrillation in minutes compare to the rests of Atrial Fibrillation in a 24 hours, as evaluated by the LifestarAct III.</description>
        <time_frame>Week 2</time_frame>
        <population>Due to software error, data could not be extracted for analysis for this outcome for all participants</population>
        <group_list>
          <group group_id="O1">
            <title>Cardiac Event Monitor</title>
            <description>Participants will under go evaluation with a two week cardiac event monitor.&#xD;
The Lifestar Act III: The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.</description>
          </group>
        </group_list>
        <measure>
          <title>Longest Duration of Atrial Fibrillation</title>
          <description>Longest duration of Atrial Fibrillation in minutes compare to the rests of Atrial Fibrillation in a 24 hours, as evaluated by the LifestarAct III.</description>
          <population>Due to software error, data could not be extracted for analysis for this outcome for all participants</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atrial Fibrillation Episodes Lasting More Than Six Minutes</title>
        <description>In participants with atrial fibrillation as evaluated by the LifestarAct III.</description>
        <time_frame>Week 2</time_frame>
        <population>Due to software error, data could not be extracted for analysis for this outcome for all participants</population>
        <group_list>
          <group group_id="O1">
            <title>Cardiac Event Monitor</title>
            <description>Participants will under go evaluation with a two week cardiac event monitor.&#xD;
The Lifestar Act III: The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Fibrillation Episodes Lasting More Than Six Minutes</title>
          <description>In participants with atrial fibrillation as evaluated by the LifestarAct III.</description>
          <population>Due to software error, data could not be extracted for analysis for this outcome for all participants</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Frequent Premature Atrial Contractions</title>
        <description>More than 100 contraction during a 24 hour period as evaluated by the LifestarAct III.</description>
        <time_frame>Week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cardiac Event Monitor</title>
            <description>Participants will under go evaluation with a two week cardiac event monitor.&#xD;
The Lifestar Act III: The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Frequent Premature Atrial Contractions</title>
          <description>More than 100 contraction during a 24 hour period as evaluated by the LifestarAct III.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two weeks</time_frame>
      <desc>Only intervention related adverse events were collected for the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cardiac Event Monitor</title>
          <description>Participants will under go evaluation with a two week cardiac event monitor.&#xD;
The Lifestar Act III: The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alberto Ramos, MD, MSPH, FAASM</name_or_title>
      <organization>University of Miami, Miller School of Medicine</organization>
      <phone>305-243-8393</phone>
      <email>a.ramos1@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

